Drug

Tretinoin

Approved · FDA

ClassRetinoic acid receptor agonistEmerging researchLate-stage developmentSteady momentum

Also known as ATRA, Acide retinoique, Altinac, Altreno+35 more

ATRA, Acide retinoique, Altinac, Altreno, Atralin, Avita, Clindamycin-Tretinoin, RETINOIC ACID, Refissa, Renova, Retin-A, Retionic acid, Solage, Tretin M, Tretin X, Tretin-X, Tretinoin Microsphere, Tretinoin Topical, Tri-Luma, Twyneo, Veltin, Vesanoid, Vitamin A acid, Ziana, all trans Retinoic acid, all trans-Retinoic acid, all-(E)-Retinoic acid, all-trans-Retinoic acid, all-trans-Tretinoin, all-trans-Vitamin A acid, all-trans-Vitamin A1 acid, all-trans-beta-Retinoic acid, beta-Retinoic acid, trans-Retinoic acid, Tretinoina, Trétinoïne, (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL), Tretinoinum.

RxNorm10753 ChEMBLCHEMBL38 ATCD10AD51 ATCL01XF01 ATCD10AD01UNII5688UTC01R

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase II Single-arm, Single-center Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer

Clinical trial2026-06-17Results expected Q4 2026 · ClinicalTrials.gov

Pilot Exploratory Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis

Clinical trial2026-06-12Results posted · ClinicalTrials.gov

Approval: TRETINOIN (ANDA214590)

Regulatory2026-06-11FDA

An Open-Label Study Evaluating the Safety and Efficacy of All-Trans Retinoic Acid in Patients With Hemophagocytic Lymphohistiocytosis

Clinical trial2026-06-04Results expected Q2 2028 · ClinicalTrials.gov

Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)

Clinical trial2026-05-20Results expected Q4 2027 · ClinicalTrials.gov

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B

Clinical trial2026-05-18Completed · ClinicalTrials.gov

Efficacy and Safety Study of Oral All-trans Retinoic Acid Combined With Toripalimab in Patients With Inoperable Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer Who Had Failed Prior Second-line or Higher Standard Therapy.

Clinical trial2026-04-30Primary completion · ClinicalTrials.gov

A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.

Clinical trial2026-04-24Results expected Q1 2029 · ClinicalTrials.gov

Differentiation of SH-SY5Y neuroblastoma cells using retinoic acid and BDNF: a model for neuronal and synaptic differentiation in neurodegeneration.

Research2024-07-17In vitro cellular & developmental biology. Animal

A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism.

Research2007-07-09The Journal of experimental medicine

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

Research1999-08-01Blood

Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons.

Research1992-05-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Tretinoin

Aliases & brands

ATRAAcide retinoiqueAltinacAltrenoAtralinAvitaClindamycin-TretinoinRETINOIC ACIDRefissaRenovaRetin-ARetionic acidSolageTretin MTretin XTretin-XTretinoin MicrosphereTretinoin TopicalTri-LumaTwyneoVeltinVesanoidVitamin A acidZianaall trans Retinoic acidall trans-Retinoic acidall-(E)-Retinoic acidall-trans-Retinoic acidall-trans-Tretinoinall-trans-Vitamin A acidall-trans-Vitamin A1 acidall-trans-beta-Retinoic acidbeta-Retinoic acidtrans-Retinoic acidTretinoinaTrétinoïne(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)Tretinoinum

RxNorm CUI

10753

ChEMBL ID

CHEMBL38

ATC codes

D10AD51L01XF01D10AD01

UNII

5688UTC01R

Primary mechanism

Retinoic acid receptor agonist

Regulatory jurisdictions

fda

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Retinoic acid receptor gamma

RARG · P13631

AGONISTRetinoic acid receptor agonist

Retinoic acid receptor beta

RARB · P10826

AGONISTRetinoic acid receptor agonist

Retinoic acid receptor alpha

RARA · P10276

AGONISTRetinoic acid receptor agonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2026-06-11

Latest approval

2026-06-11

Authorities

FDA

Total events

fdaU.S. Food and Drug Administration· 1 event

2026-06-11Approval

Approval: TRETINOIN (ANDA214590)

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).